HMPL-415S1

HMPL-415S1 is a novel, highly potent and selective allosteric inhibitor of SHP2 (Src homology-2 domain-containing protein tyrosine phosphatase 2), developed by Hutchison MediPharma (Hutchmed). SHP2 is a non-receptor protein tyrosine phosphatase that modulates diverse cell signaling events controlling metabolism, cell growth, differentiation, migration, transcription, and oncogenic transformation. It regulates key signaling pathways including RAS/ERK, PI3K/AKT, JAK/STAT and PD-1 downstream of several receptor tyrosine kinases. Dysregulation of SHP2 activity is implicated in various developmental diseases as well as hematological and solid tumors. HMPL-415S1 is being evaluated in Phase 1 clinical trials for the treatment of advanced malignant solid tumors[1][4][5].